Amneal Pharmaceuticals, Inc. has made a modest $50m raise to its full-year guidance following a successful second quarter, which saw the firm continue to shift its generics business toward complex products while its bevacizumab biosimilar exceeded expectations. The firm now expects a net revenue of $2.3bn to $2.4bn for 2023.
It has also raised its 2023 adjusted EBITDA guidance range to $525m-$540m, up about $20m from the prior range of $500m-$530m
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?